Biogen's new Alzheimer's drug slows cognitive decline: study - Boston Business Journal
Biogen: Strong Prospects With A Low Valuation (NASDAQ:BIIB) | Seeking Alpha
Biogen Seeks to Sublease Cambridge, Weston Properties - Banker & Tradesman
What clinical trials of the future might look like | Biogen
UPDATED: Biogen insists Eisai relationship 'solid' as questions remain over lecanemab commercialization | Fierce Biotech
Biogen (BIIB) Loses Bid to Revive Patent on Tecfidera MS Drug - Bloomberg
Biogen begins cutting jobs following disastrous debut of its Alzheimer's drug - The Boston Globe
Judge axes Biogen class action, rips shareholder lawyers for 'constant misrepresentation' | Reuters
Biogen gears up Swiss manufacturing facility for potential aducanumab rollout | Fierce Pharma
For women, business as unusual at Biogen - The Boston Globe
Drug companies are making an accounting change after the SEC cracked down on Biogen - MarketWatch
Biogen Uses its Own Superspreader Event to Aid COVID-19 Research | The Scientist Magazine®
Biogen - Wikipedia
Biogen Earnings Beat Expectations. All Eyes Are on the Alzheimer's Drug. | Barron's
Biogen gives up releasing Alzheimer's drug Aduhelm in Korea < Pharma < Article - KBR
How Biogen Became a Coronavirus 'Superspreader' - The New York Times
Biogen's new CEO, clear-eyed about challenges, set to take reins
Stocks making the biggest moves midday: Apple, Netflix, Biogen, Canopy Growth and more
More Layoffs Hit Biogen as Drugmaker Cuts Multiple Sclerosis Team – NBC Boston
Biogen and Novartis release Q1 earnings reports: Mixed results and hope for 2023
Dr BABOR Biogen Cellular - The Goddess Beauty and ...
Biogen - Home | Facebook
